57.41
-0.71 (-1.22%)
| Previous Close | 58.12 |
| Volume | 1,870,344 |
| Price / Earnings (Forward) | 14.36 |
| Price / Sales | 8.26 |
| Price / Book | 21.86 |
| 52 Weeks Range |
| Operating Margin (TTM) | -1,135.42% |
| Diluted EPS (TTM) | -1.71 |
| Quarterly Revenue Growth (YOY) | 5.00% |
| Total Debt/Equity (MRQ) | 297.04% |
| Current Ratio (MRQ) | 2.93 |
| Operating Cash Flow (TTM) | -99.23 M |
| Levered Free Cash Flow (TTM) | -64.38 M |
| Return on Assets (TTM) | -37.66% |
| Return on Equity (TTM) | -203.98% |
News Mood
-
LQDA Q3 Earnings Beat Estimates on Robust Yutrepia Sales
11 Nov, 10:38AM
-
Liquidia Corporation (LQDA) Q3 Earnings and Revenues Beat Estimates
10 Nov, 5:40AM
-
Liquidia Corporation Reports Third Quarter 2026 Financial Results
10 Nov, 5:30AM
-
3 Insider Selling Stories; 3 Different Signals for Investors
11 Nov, 7:10AM
-
Liquidia (LQDA) Stock Looks Rich Relative To Its Earnings Power
09 Nov, 9:11PM
AIStockmoo Score
| Value 30% | -2.5 |
| High debt. Weak profitability. Ample short-term liquidity. Negative cash flow. info | |
| From our AI Insight report's view of expected return against risk. info | NA |
| Relative Valuation info | NA |
| Implied Growth info | NA |
| Valuation History info | NA |
| Return on Capital info | NA |
| Holdings' Value info | NA |
| Risk Premium info | NA |
| Market Valuation info | NA |
| Timing 30% | -1.5 |
| No clear trend over the past year. Far below its 52-week high. info | |
| In a downtrend: the price is below its moving averages, and they are falling. It is close to them. Volume is heavier on up days. A recent move above resistance has not been confirmed. info | |
| From our AI technical analysis of the chart. info | NA |
| Candle Patterns info | NA |
| Sentiment 20% | 0.6 |
| No recent price targets, so based on how targets have been revised. info | |
| Recent news mostly positive. info | |
| Holdings' Sentiment info | NA |
| Smart Money 20% | 0.0 |
| Institutions net +0.70% of shares in their latest 13F filings: 192 holders increased, 180 decreased (quarter to 30 Sep 2026). info | |
| Short interest +47.7% from 31 Aug to 30 Oct 2026, 5.3 days to cover (FINRA). info | |
| Insider Activity info | NA |
| Market and sector conditions are poor. | |
| Market environment cautious. info | |
| Sector outperforming the market. | |
| The pillars agree, so the score is strengthened. | |
| Not in score | |
| Earnings per share have mostly fallen. Made a loss in recent years. info | |
| Below its medium-term trend line. info | |
| Price is near its 52-week average. Up over 5 years. info | |
| Short-term momentum rising. info | |
| Price is between support and resistance. Levels trending up. info | |
| Final Score | -1.28 |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Mixed | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Mixed | Mixed | |
| Stock | Liquidia Corporation | Mixed | Bullish |
Similar Stocks
| Stock | Market Cap | DY | P/E (TTM) | P/B | Score |
|---|---|---|---|---|---|
| LQDA | - | - | - | 21.86 | -1.3 |
| KNSA | 7 B | - | 71.95 | 10.51 | 1.9 |
| AMLX | 3 B | - | - | 4.70 | 0.0 |
| ETON | 2 B | - | 39.51 | 20.56 | 1.7 |
| CABR | 8 M | - | - | - | -1.6 |
| GELS | 3 M | - | - | 0.300 | -2.7 |
Select this tab to load the latest available analysis.
|
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Growth |
| % Held by Insiders | 13.64% |
| % Held by Institutions | 65.04% |
No data within this time range.
No data within this time range.
Institutions
Institutional ownership: 87.04%
| Positions | Holders | Shares |
|---|---|---|
| Increased | 192 | 8,915,003 |
| Decreased | 180 | 7,332,603 |
| New | 69 | 1,950,948 |
| Sold out | 85 | 2,906,369 |
SEC 13F filings via Nasdaq, latest filings up to 30 Sep 2026. Filings arrive up to 45 days after each quarter.
Short Interest
| Settlement | Shares | Days to cover |
|---|---|---|
| 30 Oct 2026 | 17,511,349 | 5.3 |
| 15 Oct 2026 | 17,303,701 | 2.0 |
| 30 Sep 2026 | 12,640,721 | 3.8 |
| 15 Sep 2026 | 12,377,976 | 11.4 |
| 31 Aug 2026 | 11,858,334 | 10.2 |
| 14 Aug 2026 | 11,856,100 | 6.5 |
FINRA short interest via Nasdaq, reported twice a month.
| Date | Type | Details |
|---|---|---|
| 11 Nov 2026 | Yahoo Finance |
LQDA Q3 Earnings Beat Estimates on Robust Yutrepia Sales
Liquidia's Q3 earnings and revenues beat estimates as Yutrepia sales surge, while strong PAH demand and pipeline investments support growth. |
| 11 Nov 2026 | Yahoo Finance |
LQDA Q3 Earnings Call Highlights Growth and Post-Settlement Outlook
Liquidia reports surging YUTREPIA sales, record October shipments and expanding PAH adoption amid post-settlement market changes and referral disruptions. |
| 11 Nov 2026 | Yahoo Finance |
3 Insider Selling Stories; 3 Different Signals for Investors
Insiders at Liquidia, Brinker International and Procter & Gamble have been selling shares, but context like analyst targets, institutional ownership and earnings trends shows the signals differ by company. |
| 10 Nov 2026 | Yahoo Finance |
Liquidia (LQDA) Q3 2026 Earnings Call Transcript
Record October shipments and a widening prescriber base followed a costly settlement. |
| 10 Nov 2026 | Yahoo Finance |
Liquidia Q3 Earnings Call Highlights
Liquidia (NASDAQ:LQDA) reported a 31% sequential increase in third-quarter YUTREPIA sales as the company sought to reassure investors that its pulmonary arterial hypertension business can continue growing following a patent settlement with United Therapeutics. YUTREPIA net product sales rose to $22… |
| 10 Nov 2026 | Yahoo Finance |
Liquidia Corporation to Present at 2026 Jefferies Global Healthcare Conference
MORRISVILLE, N.C., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) today announced that Dr. Roger Jeffs, Chief Executive Officer, and Michael Kaseta, Chief Operating Officer and Chief Financial Officer, will provide an update on the company’s business in a fireside chat at the… |
| 10 Nov 2026 | Yahoo Finance |
Liquidia Corporation (LQDA) Q3 Earnings and Revenues Beat Estimates
Liquidia Corporation (LQDA) delivered earnings and revenue surprises of +3.90% and +20.72%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock? |
| 10 Nov 2026 | Yahoo Finance |
Liquidia Corporation Reports Third Quarter 2026 Financial Results
YUTREPIA® (treprostinil) inhalation powder net product sales of $222.7 million in the third quarter of 2026, up 31% from the second quarter of 2026October 2026 total patient shipments reached their highest monthly level since launchResolved all litigation with United Therapeutics through a global… |
| 09 Nov 2026 | Yahoo Finance |
Liquidia (LQDA) Stock Looks Rich Relative To Its Earnings Power
Liquidia has delivered a very strong share price run in recent years, and with the stock last closing at US$47.87 the key question is whether that price can be explained by the company’s earnings power. After such a move, you need to ask if the story in the income statement keeps up with the story… |
| 03 Nov 2026 | Yahoo Finance |
Liquidia Corporation to Report Third Quarter 2026 Financial Results on November 10, 2026
MORRISVILLE, N.C., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (Nasdaq: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, announced today that it will report its third quarter 2026… |
| 30 Oct 2026 | Yahoo Finance |
Why Did Insmed Stock Jump?
For questions about this article or underlying research, email [email protected]. |
| 29 Oct 2026 | Yahoo Finance |
Stoke Therapeutics, Inc. (STOK) Reports Q3 Loss, Tops Revenue Estimates
Stoke Therapeutics (STOK) delivered earnings and revenue surprises of -22.73% and +35.88%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock? |
| 29 Oct 2026 | Yahoo Finance |
What Is Behind Liquidia's Lead Over Its Industry?
For questions about this article or underlying research, email [email protected]. |
| 28 Oct 2026 | Yahoo Finance |
Liquidia Gears Up to Report Q3 Earnings: What Can Investors Expect?
LQDA's Q3 results will spotlight the impact of its legal settlement with UTHR, cash flow pressures, profitability prospects and pipeline progress. |
| Show more | ||
Recent Signals candle patterns and EMA crosses
Technical Setup Medium
AI Technical Analysis
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |